Abstract:Background: Candida albicans is an opportunistic pathogen commonly found in human mucous membranes. In light of the escalating challenge posed by antibiotic resistance of C. albicans strains worldwide, it is an urgently necessary to explore alternative therapeutic options. Objective: This study aims to assess the efficacy of two Cinnamaldehyde derivatives, 2-Cl Cinnamaldehyde (2-Cl CA) and 4-Cl Cinnamaldehyde (4-Cl CA), against C. albicans through both in vitro experiments and in vivo murine models and to evaluate their potential as new drug candidates for treating C. albicans. Methods and results: The minimum inhibitory concentrations (MICs) of Cinnamaldehyde 2-Cl and 4-Cl benzene ring derivatives against C. albicans were 25 μg/mL. Time-killing experiments revealed that both Cinnamaldehyde derivatives exhibited fungicidal activity against C. albicans at concentrations of 5 MIC and 10 MIC. In the checkerboard experiment, 4-Cl CA did not show any antagonistic effect when combined with first-line antifungal drugs. Instead, it exhibited additive effects in combination with nystatin. Both 2-Cl and 4-Cl CA demonstrated inhibitory activity against C. albicans biofilm formation, especially at 8 MIC and 16 MIC concentrations. In C. albicans biofilm eradication experiments, although high drug concentrations of 2-Cl and 4-Cl CA were unable to eradicate the biofilm completely, they were still effective in killing C. albicans cells within the biofilm. Moreover, sub-inhibitory concentrations of 4-Cl CA (ranging from 5 to 20 μg/mL) significantly inhibited cell aggregation and hyphal formation. Furthermore, 4-Cl CA effectively inhibited intracellular C. albicans infection in macrophages. Lastly, the effectiveness of 4-Cl CA was evaluated in a mouse model of hematogenous disseminated candidiasis caused by C. albicans, which revealed that 4-Cl CA significantly reduced fungal burden and improved mouse survival compared to the untreated controls. Conclusion: The 4-Cl CA exhibited inhibitory effects against C. albicans through both in vivo and in vitro models, demonstrating its therapeutic potential as a promising new drug candidate for treating drug-resistant candidiasis albicans.

Antifungal Activity of Geldanamycin Alone or in Combination with Fluconazole Against Candida Species

In Vitro Interactions of Micafungin with Amphotericin B, Itraconazole or Fluconazole Against the Pathogenic Phase of Penicillium Marneffei.

Comparative Evaluation of ATB FUNGUS 3 Procedure and CLSI M27-A2 Broth Microdilution Method for Antifungal Susceptibility Testing of Pathogenic Yeasts

The Effect of Ginkgolide B Combined with Fluconazole Against Drug-Resistant Candida Albicans Based on Common Resistance Mechanisms

Geldanamycin confers fungicidal properties to azole by triggering the activation of succinate dehydrogenase

Anti- Candida Activity of New Azole Derivatives Alone and in Combination with Fluconazole

Synergistic Antifungal Effect of Fluconazole Combined with Licofelone Against Resistant Candida Albicans

The synergy of honokiol and fluconazole against clinical isolates of azole-resistant Candida albicans

In vitro antifungal activity of micafungin against clinical strains of Candida spp. and Aspergillus spp. isolated from China

In vitro synergy of pseudolaric acid B and fluconazole against clinical isolates of Candida albicans: Synergy of PAB and FLC against Candida albicans

Antifungal activity of Cinnamaldehyde derivatives against fluconazole-resistant Candida albicans

Pseudolaric Acid A: A Promising Antifungal Agent Against Prevalent Non- albicans Candida Species

The synergistic antifungal effect and potential mechanism of D-penicillamine combined with fluconazole against Candida albicans

Antifungal evaluation of quinoline-chalcone derivatives combined with FLC against drug-resistant Candida albicans.

In Vitro Synergistic Antifungal Activities of Caspofungin in Combination with Fluconazole or Voriconazole Against Candida Species Determined by the Etest Method

Ellagic Acid Potentiates the Inhibitory Effects of Fluconazole Against Candida albicans

Antifungal Activity and Potential Mechanism of 6,7, 4′-O-Triacetylscutellarein Combined With Fluconazole Against Drug-Resistant C. albicans

Paeonol assists fluconazole and amphotericin B to inhibit virulence factors and pathogenicity of Candida albicans

Effects of Geldanamycin on Gallbladder Carcinoma in Vitro

Antifungal Effects of Phytocompounds on Candida Species Alone and in Combination with Fluconazole.

In vitro and in vivo analysis of monotherapy and dual therapy with ethyl caffeate and fluconazole on virulence factors of Candida albicans and systemic candidiasis